BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

...EPFL) Genentech Inc. Programmed cell death 1 (PD-1) (PDCD1) (CD279) Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) c-Mer proto-oncogene tyrosine kinase (MERTK) COVID-19...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...protein tyrosine kinase Karen Tkach Tuzman, Associate Editor Arcus Biosciences Inc. Celldex Therapeutics Inc. Merrimack Pharmaceuticals Inc. Meryx Inc. MiNA Therapeutics Ltd. c-Mer proto-oncogene tyrosine kinase (MERTK) Chemokine...
BioCentury | Feb 8, 2019
Company News

BioMotiv, Rutgers launch TamRx

...Cleveland, Ohio BioMotiv LLC, Cleveland, Ohio Business: Cancer Mark Zipkin BioMotiv LLC Rutgers University AXL receptor tyrosine kinase (AXL) (UFO) c-Mer proto-oncogene tyrosine kinase (MERTK) Growth...
BioCentury | Feb 7, 2019
Company News

BioMotiv, Rutgers launch TamRx

...kinase; TYRO3 (Sky) - TYRO3 protein tyrosine kinase Mark Zipkin BioMotiv LLC Rutgers University AXL receptor tyrosine kinase (AXL) (UFO) c-Mer proto-oncogene tyrosine kinase (MERTK) Growth...
BioCentury | May 11, 2018
Clinical News

Mirati reports updated Phase II data for sitravatinib, Opdivo combo

...BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Sitravatinib (MGCD516, mg516) Mirati Therapeutics Inc. AXL receptor tyrosine kinase (AXL) (UFO) c-Mer proto-oncogene tyrosine kinase (MERTK) Programmed...
BioCentury | Jan 15, 2018
Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

...OSE:BGBIO) and CT413 from HEC Pharm Group (Dongguan, China), a dual inhibitor of AXL and c-Mer proto-oncogene tyrosine kinase (MERTK)...
BioCentury | Jan 4, 2018
Distillery Therapeutics

Ophthalmic disease

...RPE65, LRAT or MERTK. TARGET/MARKER/PATHWAY: Retinal pigment epithelium-specific protein 65kDa (RPE65); lecithin retinol acyltransferase (LRAT); c-Mer proto-oncogene tyrosine kinase (MERTK)...
...INSERM), Paris, France email: cmonville@istem.fr Chris Lieu Institut National de la Sante et de la Recherche Medicale (INSERM) c-Mer proto-oncogene tyrosine kinase (MERTK) Lecithin...
BioCentury | Dec 21, 2017
Preclinical News

Researchers develop hESC-derived RPE cell sheet

...retinitis pigmentosa caused by mutations in RPE-specific protein 65kDa (RPE65), lecithin retinol acyltransferase (LRAT) or c-Mer proto-oncogene tyrosine kinase (MERTK)...
...Pharma Inc. BioTime Inc. Institut National de la Sante et de la Recherche Medicale (INSERM) Pfizer Inc. Riken Spark Therapeutics Inc. c-Mer proto-oncogene tyrosine kinase (MERTK) Retinal...
BioCentury | Sep 22, 2017
Clinical News

Mirati reports partial responses in Phase II NSCLC trial of sitravatinib

...Ret proto-oncogene (RET), TYRO3 protein tyrosine kinase (TYRO3; SKY), AXL receptor tyrosine kinase (AXL; UFO), c-Mer proto-oncogene tyrosine kinase (MERTK)...
...inhibits multiple receptor tyrosine kinases (RTKs) including RET, TYRO3, AXL receptor tyrosine kinase (AXL; UFO), c-Mer proto-oncogene tyrosine kinase (MERTK)...
...pharmacokinetics Status: Phase II data Milestone: NA Jaime De Leon MGCD516 sitravatinib Mirati Therapeutics Inc. AXL receptor tyrosine kinase (AXL) (UFO) c-Mer proto-oncogene tyrosine kinase (MERTK) Ret...
BioCentury | Sep 15, 2017
Clinical News

Mirati, Loxo gain on RET inhibitor presentations

...RTKs) including RET, TYRO3 protein tyrosine kinase (TYRO3; SKY), AXL receptor tyrosine kinase (AXL; UFO), c-Mer proto-oncogene tyrosine kinase (MERTK)...
Items per page:
1 - 10 of 23